Targeting Pim kinases in hematological cancers: molecular and clinical review

32Citations
Citations of this article
69Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Decades of research has recognized a solid role for Pim kinases in lymphoproliferative disorders. Often up-regulated following JAK/STAT and tyrosine kinase receptor signaling, Pim kinases regulate cell proliferation, survival, metabolism, cellular trafficking and signaling. Targeting Pim kinases represents an interesting approach since knock-down of Pim kinases leads to non-fatal phenotypes in vivo suggesting clinical inhibition of Pim may have less side effects. In addition, the ATP binding site offers unique characteristics that can be used for the development of small inhibitors targeting one or all Pim isoforms. This review takes a closer look at Pim kinase expression and involvement in hematopoietic cancers. Current and past clinical trials and in vitro characterization of Pim kinase inhibitors are examined and future directions are discussed. Current studies suggest that Pim kinase inhibition may be most valuable when accompanied by multi-drug targeting therapy.

Cite

CITATION STYLE

APA

Bellon, M., & Nicot, C. (2023, December 1). Targeting Pim kinases in hematological cancers: molecular and clinical review. Molecular Cancer. BioMed Central Ltd. https://doi.org/10.1186/s12943-023-01721-1

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free